Novavax, Inc.
↗Gaithersburg, Maryland, USA
Novavax is a vaccine company headquartered in Gaithersburg, Maryland that develops vaccines using its proprietary protein-based nanoparticle platform and Matrix-M adjuvant technology. The company achieved prominence during the COVID-19 pandemic with its Nuvaxovid vaccine, which is the only non-mRNA COVID-19 vaccine authorized in the U.S. Novavax has transitioned from a struggling biotech to a growing vaccine company, with significant partnerships with Sanofi and Pfizer. The company is now advancing combination vaccines combining COVID-19 and influenza protection, as well as exploring applications in oncology and other therapeutic areas.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$1.1B (2025)
Founded:1987
Ownership:public
Status:operating
FUNDING
Stage:Public
Investors:Sanofi (recent investment <5%), Operation Warp Speed ($1.6B during COVID-19)
STOCK
Exchange:NASDAQ
Ticker:NVAX
Market Cap:$1.67B
PIPELINE
Stage:Commercial + Phase 3
Lead Drug Stage:Commercial (Nuvaxovid COVID-19 vaccine)
Modalities:Protein-based nanoparticles, Adjuvanted vaccines
Active Trials:3
Trial Phases:Phase 2: 1 | Phase 3: 2
FDA Approvals:1
EMA Approvals:1
CORPORATE STRUCTURE
Subsidiaries:Novavax AB (Sweden)
Key Partnerships:Sanofi: $1.4B co-exclusive licensing deal (May 2024) for COVID vaccine co-commercialization and combination vaccine development, Pfizer: $530M non-exclusive license for Matrix-M adjuvant use (January 2026), Bill & Melinda Gates Medical Research Institute: Collaboration for Matrix-M research (2023), Gavi/COVAX: Support for vaccine distribution to low/middle-income countries, Serum Institute of India: Manufacturing partner for vaccine production
COMPETITION
Position:Challenger
Competitors:Pfizer (mRNA COVID-19 and combo vaccines), Moderna (mRNA COVID-19 and combo vaccines), Sanofi (influenza vaccines - now also distribution partner), GSK (influenza and other vaccines), Johnson & Johnson (vaccines)
LEADERSHIP
Key Executives:
John C. Jacobs - President & Chief Executive Officer
Margaret G. McGlynn, RPh - Board Chair
John Trizzino - President & Chief Operating Officer
James P. Kelly - Executive Vice President & Chief Financial Officer
Mark J. Casey - Executive Vice President & Chief Legal Officer
Ruxandra Draghia-Akli, MD, PhD - Executive Vice President, Head of Research & Development
Elaine O'Hara - Executive Vice President & Chief Strategy Officer
Scientific Founders:Michael Houghton (founder, 1987)
Board Members:Margaret McGlynn (Chair), John C. Jacobs (CEO/Director), John Shiver, PhD (appointed 2025), Charles Newton (appointed April 2025)
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Novavax, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Novavax, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.